

Key Statistics

(as of March 2011)

Ticker.....VYST.OB
Sector..... Specialty Chemicals
IndustryBasic Materials
Shares Outstanding15.17M
Market Cap.....\$10.31M

Management

Bill Doyle
President
Chief Executive Officer

Sandra Parker
Executive VP of Business
Development & Marketing

Jack Callicutt, CPA
Chief Financial Officer

Matt Clark
VP of Technical Sales

Investor Relations

The Investor Relations Group
11 Stone Street
New York, NY 10004
Tel.: (212) 825-3210
Fax: (212) 825-3229

Investor Relations
Adam Holdsworth
James Carbonara

Public Relations
Janet Vasquez
Laura Colontrelle

About Vystar[®] Corporation

Based near Atlanta, GA, Vystar[®] Corporation (OTC BB: VYST.OB) is the creator of Vytex[®] Natural Rubber Latex (NRL), a multi-patented, all-natural raw material that significantly reduces antigenic proteins found in over 40,000 products made with natural rubber latex. The first product made with Vytex NRL, the Envy[™] Ultra Thin condom, which is manufactured by Alatech Healthcare LLC of Eufaula, AL, was introduced to the US market in 2009 and carries the only antigenic protein claim with less than 2 micrograms/dm². This product gives the consumer firsthand experience with the remarkable benefits of Vytex NRL. In addition, Alatech received FDA 510(k) clearance for exam gloves made with Vytex NRL. Vystar is also working with manufacturers across a broad range of consumer and medical products to bring Vytex NRL to market in adhesives, surgical and exam gloves, condoms, balloons, and natural rubber latex foam mattresses, pillows and sponges. For more information, visit vytex.com.



Created by Nature. Recreated by Science.[®]

Latex Allergy Is A Problem

Products Manufactured from Vytex NRL May Reduce the Risk of Latex Sensitivity



Natural rubber latex (NRL) is the material of choice in thousands of consumer and medical products. However, NRL, similar to other natural plant materials contains over 200 proteins, 13 of which are suspected allergens. These antigenic proteins can cause allergic reactions in latex-sensitive people. Reactions can range from minor skin irritation and redness to sneezing or even anaphylactic shock, a serious condition that requires immediate medical attention. *Published data indicate that 1% to 6% of the general public has some level of latex allergy.*

Vytex NRL: The Future of Latex

Natural Rubber Latex: Nature Made it Good, Vytex NRL Made it Better

Vytex NRL is a revolutionary new raw material that establishes a new standard of NRL that has ultra-low levels of antigenic protein. Prior to the introduction of Vytex NRL efforts to meet the demand for better latex products involved switching to synthetic substitutes. These synthetic substitutes lack many of NRL's desirable benefits and exhibit lower elasticity, barrier protection, tensile strength, modulus and tactile sensitivity.



Vytex NRL is produced through patented processes using green chemistry that significantly reduce the antigenic proteins in liquid latex. Because of this unique process, Vytex NRL is a much more stable latex compound compared to regular NRL. Also, because the non-rubber impurities are removed, products made from Vytex NRL retain the positive attributes of NRL but without most of the allergy-causing proteins.

What Is Natural Rubber Latex And Where Is It Produced?



Vytex NRL Is Produced at the Latex Processor Level Using Vystar's Patented Processes To Scientifically Transform NRL to Remove Allergy-Related Proteins

- Protective white fluid contained in tissue beneath the bark of the rubber tree, *Hevea brasiliensis*, is collected by shaving a thin strip of bark from the tree
- Latex is secreted into a collection cup over a period of several hours
- Consists of approximately 30-40% rubber particles, 55-65% water and other non-rubber substances
- 90% of the NRL supply comes from production plants in Southeast Asia locations such as Thailand, Malaysia, and Indonesia.

FDA 510(k) Clearances for Condoms and Exam Gloves



Envy™ Condom:

- Envy™ is the first condom brand produced using Vytex NRL and carries the only antigenic protein claim on the market today
- The product has proven strength, protection, fit, and sex-enhancing sensitivity of ultra-thin latex condoms while reducing the risk of exposure to latex allergens and virtually eliminating the odor found with traditional latex condoms
- Commercially available on Condomania.com




Exam Gloves:

- First exam gloves manufactured with Vytex NRL
- Specific need for reduced antigenic proteins in natural rubber latex with approximately 17% of healthcare workers who show sensitivity to NRL

Significant Market Opportunities

Many manufacturing trials are underway worldwide for gloves and other products made with Vytex NRL including medical and non-medical gloves, condoms, balloons, foam mattresses and pillows, bandages, adhesives and more.

Market Potential: 1.3 Million Metric Tons Annually (2010)



Vystar Covers All Bases

Business relationships that span the globe are fueling the Vytex NRL revolution. More and more manufacturers are evaluating and adopting Vytex NRL within their own production environment and looking toward relationships with Vystar, creator of Vytex NRL.

Key Relationships

Centrotrade: Exclusive Vytex NRL distribution partner; North America & Europe

Revertex Malaysia: Toll manufacturing agreement to produce Vytex NRL
Grupo Agroindustrial Occidente: Exclusive Licensor of Vytex NRL in Latin and South America and the Caribbean

Source: International Rubber Study Group, 2006



Printed on paperboard made from 100% total recycled content, minimum 30% post-consumer content

Disclaimer:

The information disseminated by the Investor Relations Group ("IRG," "us" or "we") is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. We do not undertake or purport to render any investment advice or recommendations for the buying and selling of securities. Companies that are profiled may have engaged our services to perform investor relation services including promotional services and the placement of the profiled companies on our website. IRG's compensation for such services has been or will be made in cash and/or issuance of securities of the profiled company, the amount or type of compensation is available upon request. We may liquidate any securities that we receive as compensation when deemed appropriate to do so. The assembled information herein is based on information supplied by the company, press releases, SEC filings, or from other sources believed to be reliable as of the date of the report on the featured companies, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. It is subject to change without notice. IRG and its affiliates are not, nor claim to be: brokers, broker-dealers, market makers, investment bankers, advisors, analysts or underwriters. Information in email alerts, Fact Sheets and other forms of informational media provided by us will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Forward looking statements are subject to a number of known and unknown risks and uncertainties outside our control that could cause actual operations or results to differ materially from those anticipated. The cautionary statements made herein should be read as being applicable to all related forward-looking statements wherever they appear on this site or in other communications. We encourage you to visit the Securities Exchange Commission web site <http://www.sec.gov>.